Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMG-100
- Development stage
- Unknown
- Lead developer
- OMG Pharma
- Modality
- Small Molecules
- Administration
- Oral, Sublingual, Buccal
01
Overview
OMG-100 is an oral dissolving tablet (ODT) formulation of cannabidiol (CBD) being developed by OMG Pharma for the treatment of insomnia disorder. The product utilizes a proprietary delivery technology designed to enhance the bioavailability and pharmacokinetic profile of CBD by facilitating mucosal absorption in the oral cavity, thereby bypassing first-pass hepatic metabolism. This delivery method aims to provide a faster onset of action and more consistent therapeutic levels compared to traditional oral CBD oils or capsules. OMG-100 is currently being evaluated in clinical trials to assess its safety, tolerability, and efficacy in improving sleep quality and duration in patients with insomnia.
- Other names
- cannabidiolCBD
Beyond the preview
Go deeper on OMG-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMG-100.